Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors This paper is dedicated to the memory of Prof. Donald F. Steiner (1930-2014) - Advisor, mentor, and discoverer of proinsulin.

Pharmacological Research

Volumn 94, Issue , 2015, Pages 9-25

  Roskoski, Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

BCR Abl; Catalytic spine; Regulatory spine; SH2 domain; SH3 domain; Targeted cancer therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; AZD 0424; BOSUTINIB; DASATINIB; MAGNESIUM ION; MEMBRANE PROTEIN; PHOSPHATASE; PONATINIB; PROTEIN SH1; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; SRC PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VANDETANIB; MAGNESIUM; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BILE DUCT CARCINOMA; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DRUG APPROVAL; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME REGULATION; ENZYME STABILITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG SARCOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MOLECULAR DYNAMICS; NON SMALL CELL LUNG CANCER; OSTEOSARCOMA; OVARY CANCER; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; THYROID MEDULLARY CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; MAGNESIUM; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SRC-FAMILY KINASES;

EID: 84923102615     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.01.003     Document Type: Review

References (107)

1. P. Rous A sarcoma of the fowl transmissible by an agent separable from the tumor cells J Exp Med 13 1911 397 411
2. D. Stehelin, H.E. Varmus, J.M. Bishop, and P.K. Vogt DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA Nature 260 1976 170 173
3. M.T. Brown, and J.A. Cooper Regulation, substrates and functions of src Biochim Biophys Acta 1287 1996 121 149
4. S.M. Thomas, and J.S. Brugge Cellular functions regulated by Src family kinases Annu Rev Cell Dev Biol 13 1997 513 609
5. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
6. R. Roskoski Jr. MEK1/2 dual-specificity protein kinases: structure and regulation Biochem Biophys Res Commun 417 2012 5 10
7. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, and A. Osterman Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711
8. P.J. Mitchell, K.T. Barker, J.E. Martindale, T. Kamalati, P.N. Lowe, and M.J. Page Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours Oncogene 9 1994 2383 2390
9. src, a retroviral transforming protein Science 227 1985 427 429
10. J.M. Kaplan, G. Mardon, J.M. Bishop, and H.E. Varmus The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant Mol Cell Biol 8 1988 2435 2441
11. E.C. Gaffarogullari, L.R. Masterson, E.E. Metcalfe, N.J. Traaseth, E. Balatri, and M.M. Musa A myristoyl/phosphoserine switch controls cAMP-dependent protein kinase association to membranes J Mol Biol 411 2011 823 836
12. O. Hantschel, B. Nagar, S. Guettler, J. Kretzschmar, K. Dorey, and J. Kuriyan A myristoyl/phosphotyrosine switch regulates c-Abl Cell 112 2003 845 857
13. A.A. Adzhubei, M.J. Sternberg, and A.A. Makarov Polyproline-II helix in proteins: structure and function J Mol Biol 425 2013 2100 2132
14. B.A. Liu, B.W. Engelmann, and P.D. Nash The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction FEBS Lett 586 2012 2597 2605
15. Z. Songyang, and L.C. Cantley Recognition and specificity in protein tyrosine kinase-mediated signaling Trends Biochem Sci 20 1995 470 475
16. G. Waksman, and J. Kuriyan Structure and specificity of the SH2 domain Cell 116 2004 S45 S48
17. X.M. Zheng, R.J. Resnick, and D. Shalloway A phosphotyrosine displacement mechanism for activation of Src by PTPα EMBO J 19 2000 964 978
18. c-src: implications for regulation Science 231 1986 1431 1434
19. c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation Cell 49 1987 65 73
20. c-src function J Biol Chem 264 1989 20886 20893
21. M. Odada Regulation of the Src family kinases by Csk Int J Biol Sci 8 2012 1385 1397
22. S. Zrihan-Licht, J. Lim, I. Keydar, M.X. Sliwkowski, J.E. Groopman, and H. Avraham Association of Csk-homologous kinase [CHK] [formerly MATK] with HER-2/ErbB-2 in breast cancer cells J Biol Chem 272 1997 1856 1863
23. S.S. Taylor, M.M. Keshwani, J.M. Steichen, and A.P. Kornev Evolution of the eukaryotic protein kinases as dynamic molecular switches Philos Trans R Soc Lond B Biol Sci 367 2012 2517 2528
24. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, and S.S. Taylor Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
25. S.C. Harrison Variation on an Src-like theme Cell 112 2003 737 740
26. W. Xu, A. Doshi, M. Lei, M.J. Eck, and S.C. Harrison Crystal structures of c-Src reveal features of its autoinhibitory mechanism Mol Cell 3 1999 629 638
27. R. Roskoski Jr. Src kinase regulation by phosphorylation and dephosphorylation Biochem Biophys Res Commun 331 2005 1 14
28. G. Sun, L. Ramdas, W. Wang, J. Vinci, J. McMurray, and R.J. Budde Effect of autophosphorylation on the catalytic and regulatory properties of protein tyrosine kinase Src Arch Biochem Biophys 397 2002 11 17
29. A. Palmer, M. Zimmer, K.S. Erdmann, V. Eulenburg, A. Porthin, and R. Heumann EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase Mol Cell 9 2002 725 737
30. R. Roskoski Jr. Src protein-tyrosine kinase structure and regulation Biochem Biophys Res Commun 324 2004 1155 1164
31. Y.P. Chong, T.D. Mulhern, H.J. Zhu, D.J. Fujita, J.D. Bjorge, and J.P. Tantiongco A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity J Biol Chem 279 2004 20752 20766
32. G. Sun, A.J. Sharma, and R.J. Budde Autophosphorylation of Src and Yes blocks their inactivation by Csk phosphorylation Oncogene 17 1998 1587 1595
33. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem Sci 36 2011 65 77
34. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc Natl Acad Sci U S A 103 2006 17783 17788
35. H.S. Meharena, P. Chang, M.M. Keshwani, K. Oruganty, A.K. Nene, and N. Kannan Deciphering the structural basis of eukaryotic protein kinase regulation PLoS Biol 11 2013 e1001680
36. K. Shah, Y. Liu, C. Deirmengian, and K.M. Shokat Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates Proc Natl Acad Sci U S A 94 1997 3565 3570
37. Y. Liu, K. Shah, F. Yang, L. Witucki, and K.M. Shokat A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src Bioorg Med Chem 6 1998 1219 1226
38. M.A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D.E. Shaw, and N.P. Shah Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res 69 2009 2384 2392
39. S.S. Taylor, E. Radzio-Andzelm, and T. Hunter How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase FASEB J 9 1995 1255 1266
40. W. Xu, S.C. Harrison, and M.J. Eck Three-dimensional structure of the tyrosine kinase c-Src Nature 385 1997 595 602
41. J.C. Williams, A. Weijland, S. Gonfloni, A. Thompson, S.A. Courtneidge, and G. Superti-Furga The 2.35 crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions J Mol Biol 274 1997 757 775
42. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nat Chem Biol 10 2014 127 132
43. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
44. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
45. R.A. Steinberg, R.D. Cauthron, M.M. Symcox, and H. Shuntoh Autoactivation of catalytic [Cα] subunit of cyclic AMP-dependent protein kinase by phosphorylation of threonine 197 Mol Cell Biol 13 1993 2332 2341
46. Y. Meng, and B. Roux Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop J Mol Biol 426 2014 423 435
47. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nat Chem Biol 2 2006 358 364
48. A. Fersht Enzyme structure and mechanism 2nd ed. 1985 WH Freeman and Company New York 105 106
49. G. Sun, and R.J. Budde Requirement for an additional divalent metal cation to activate protein tyrosine kinases Biochemistry 36 1997 2139 2146
50. P.F. Cook, M.E. Neville Jr., K.E. Vrana, F.T. Hartl, and R. Roskoski Jr. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit Biochemistry 21 1982 5794 5799
51. B. Lovitt, E.C. Vanderporten, Z. Sheng, H. Zhu, J. Drummond, and Y. Liu Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 [LRRK2] Biochemistry 49 2010 3092 3100
52. M. Liu, E. Girma, M.A. Glicksman, and R.L. Stein Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect Biochemistry 49 2010 4921 4929
53. W.F. Waas, and K.N. Dalby Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2 Biochemistry 42 2003 2960 2970
54. 2+ of interleukin-1 receptor-associated kinase-4 Biochemistry 49 2010 1495 1506
55. P.P. Vicario, R. Saperstein, and A. Bennun Role of divalent metals in the kinetic mechanism of insulin receptor tyrosine kinase Arch Biochem Biophys 261 1988 336 345
56. P. Saylor, C. Wang, T.J. Hirai, and J.A. Adams A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps Biochemistry 37 1998 12624 12630
57. D.M. Jacobsen, Z.Q. Bao, P. O'Brien, C.L. Brooks 3rd, and M.A. Young Price to be paid for two-metal catalysis: magnesium ions that accelerate chemistry unavoidably limit product release from a protein kinase J Am Chem Soc 134 2012 15357 15370
58. L. Lin, R. Czerwinski, K. Kelleher, M.M. Siegel, P. Wu, and R. Kriz Activation loop phosphorylation modulates Bruton's tyrosine kinase [Btk] kinase domain activity Biochemistry 48 2009 2021 2032
59. P.S. Brignola, K. Lackey, S.H. Kadwell, C. Hoffman, E. Horne, and H.L. Carter Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors J Biol Chem 277 2002 1576 1585
60. G. Sun, and R.J. Budde Expression, purification, and initial characterization of human Yes protein tyrosine kinase from a bacterial expression system Arch Biochem Biophys 345 1997 135 142
61. C.V. Parast, B. Mroczkowski, C. Pinko, S. Misialek, G. Khambatta, and K. Appelt Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase [VEGFR2 TK], a key enzyme in angiogenesis Biochemistry 37 1998 16788 16801
62. R.N. Armstrong, H. Kondo, J. Granot, E.T. Kaiser, and A.S. Mildvan Magnetic resonance and kinetic studies of the manganese [II] ion and substrate complexes of the catalytic subunit of adenosine 3′,5′-monophosphate dependent protein kinase from bovine heart Biochemistry 18 1979 1230 1238
63. J. Zheng, D.R. Knighton, L.F. ten Eyck, R. Karlsson, N. Xuong, and S.S. Taylor Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor Biochemistry 32 1993 2154 2161
64. J.A. Adams, and S.S. Taylor Divalent metal ions influence catalysis and active-site accessibility in the cAMP-dependent protein kinase Protein Sci 2 1993 2177 2186
65. J. Zhou, and J.A. Adams Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase Biochemistry 36 1997 15733 15738
66. J.A. Adams Kinetic and catalytic mechanisms of protein kinases Chem Rev 101 2001 2271 2290
67. A.C. Bastidas, M.S. Deal, J.M. Steichen, Y. Guo, J. Wu, and S.S. Taylor Phosphoryl transfer by protein kinase A is captured in a crystal lattice J Am Chem Soc 135 2013 4788 4798
68. O. Gerlits, A. Das, M.M. Keshwani, S. Taylor, M.J. Waltman, and P. Langan Metal-free cAMP-dependent protein kinase can catalyze phosphoryl transfer Biochemistry 53 2014 3179 3186
69. 2+-independent neurexin kinase Cell 133 2008 328 339
70. Y.H. Peng, H.Y. Shiao, C.H. Tu, P.M. Liu, J.T. Hsu, and P.K. Amancha Protein kinase inhibitor design by targeting the Asp-Phe-Gly [DFG] motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors J Med Chem 56 2013 3889 3903
71. R. Roskoski Jr. The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol Res 79 2014 34 74
72. R. Roskoski Jr. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors Pharmacol Res 87 2014 42 59
73. J.J. Cui Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress J Med Chem 57 2014 4427 4453
74. J. Gao, Y. Inagaki, P. Song, X. Qu, N. Kokudo, and W. Tang Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma Pharmacol Res 65 2012 23 30
75. C.H. Heldin Targeting the PDGF signaling pathway in tumor treatment Cell Commun Signal 11 2013 97
76. J.A. Janssen, and A.J. Varewijck IGF-IR targeted therapy: past, present and future Front Endocrinol (Lausanne) 5 2014 224
77. A. Arcaro Targeting the insulin-like growth factor-1 receptor in human cancer Front Pharmacol 4 2013 30
78. J. Wesche, K. Haglund, and E.M. Haugsten Fibroblast growth factors and their receptors in cancer Biochem J 437 2011 199 213
79. S. Zhang, and D. Yu Targeting Src family kinases in anti-cancer therapies: turning promise into triumph Trends Pharmacol Sci 33 2012 122 128
80. R. Roskoski Jr. Protein prenylation: a pivotal posttranslational process Biochem Biophys Res Commun 303 2003 1 7
81. L.N. Puls, M. Eadens, and W. Messersmith Current status of SRC inhibitors in solid tumor malignancies Oncologist 16 2011 566 578
82. A.I. Daud, S.S. Krishnamurthi, M.N. Saleh, B.J. Gitlitz, M.J. Borad, and P.J. Gold Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors Clin Cancer Res 18 2012 1092 1100
83. B. Moy, P. Neven, F. Lebrun, M. Bellet, B. Xu, and T. Sarosiek Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer Oncologist 19 2014 348 349
84. J. Araujo, and C. Logothetis Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors Cancer Treat Rev 36 2010 492 500
85. J.E. Cortes, D.W. Kim, J. Pinilla-Ibarz, P. le Coutre, R. Paquette, and C. Chuah A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias N Engl J Med 369 2013 1783 1796
86. M.W. Sim, and M.S. Cohen The discovery and development of vandetanib for the treatment of thyroid cancer Expert Opin Drug Discov 9 2014 105 114
87. C. Gridelli, S. Novello, N. Zilembo, A. Luciani, A.G. Favaretto, and F. De Marinis Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients J Thorac Oncol 9 2014 733 737
88. J.S. Ahn, K.H. Lee, J.M. Sun, K. Park, E.S. Kang, and E.K. Cho A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy Lung Cancer 82 2013 455 460
89. S.A. Laurie, G.D. Goss, F.A. Shepherd, M.N. Reaume, G. Nicholas, and L. Philip A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the Princess Margaret Hospital phase II consortium Clin Lung Cancer 15 2014 52 57
90. D.H. Boschelli, Y.D. Wang, S. Johnson, B. Wu, F. Ye, and A.C. Barrios Sosa 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases J Med Chem 47 2004 1599 1601
91. L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, and K. Behnia Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 2004 6658 6661
92. W.S. Huang, C.A. Metcalf, R. Sundaramoorthi, Y. Wang, D. Zou, and R.M. Thomas Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant J Med Chem 53 2010 4701 4719
93. L.F. Hennequin, J. Allen, J. Breed, J. Curwen, M. Fennell, and T.P. Green N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J Med Chem 49 2006 6465 6488
94. D. Nowak, S. Boehrer, S. Hochmuth, B. Trepohl, W. Hofmann, and D. Hoelzer Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells Anticancer Drugs 18 2007 981 995
95. L.F. Hennequin, E.S. Stokes, A.P. Thomas, C. Johnstone, P.A. Plé, and D.J. Ogilvie Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors J Med Chem 45 2002 1300 1312
96. D.A. Johnson, P. Akamine, E. Radzio-Andzelm, M. Madhusudan, and S.S. Taylor Dynamics of cAMP-dependent protein kinase Chem Rev 101 2001 2243 2270
97. M. Azam, M.A. Seeliger, N.S. Gray, J. Kuriyan, and G.Q. Daley Activation of tyrosine kinases by mutation of the gatekeeper threonine Nat Struct Mol Biol 15 2008 1109 1118
98. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 66 2012 105 143
99. M. Getlik, C. Grütter, J.R. Simard, S. Klüter, M. Rabiller, and H.B. Rode Hybrid compound design to overcome the gatekeeper T338 M mutation in cSrc J Med Chem 52 2009 3915 3926
100. W. Eckhart, M.A. Hutchinson, and T. Hunter An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates Cell 18 1979 925 933
101. T. Hunter, and B.M. Sefton Transforming gene product of Rous sarcoma virus phosphorylates tyrosine Proc Natl Acad Sci U S A 77 1980 1311 1315
102. A.P. Czernilofsky, A.D. Levinson, H.E. Varmus, J.M. Bishop, E. Tischer, and H.M. Goodman Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product Nature 287 1980 198 203
103. A.P. Czernilofsky, A.D. Levinson, H.E. Varmus, J.M. Bishop, E. Tischer, and H. Goodman Corrections to the nucleotide sequence of the src gene of Rous sarcoma virus Nature 301 1983 736 738
104. S. Shoji, D.C. Parmelee, R.D. Wade, S. Kumar, L.H. Ericsson, and K.A. Walsh Complete amino acid sequence of the catalytic subunit of bovine cardiac muscle cyclic AMP-dependent protein kinase Proc Natl Acad Sci U S A 78 1981 848 851
105. W.C. Barker, and M.O. Dayhoff Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase Proc Natl Acad Sci U S A 79 1982 2836 2839
106. 14C]benzoyl 5′-adenosine. Identification of a modified lysine residue J Biol Chem 1979 254 1979 8363 8368
107. P. Cohen, and D.R. Alessi Kinase drug discovery - what's next in the field? ACS Chem Biol 8 2013 96 104